In vivo selection of bioprocessable biopharmaceuticals
Lead Research Organisation:
University of Leeds
Department Name: Astbury Centre
Abstract
Biopharmaceuticals (or biologics) are medicines that are made from biological materials, most usually proteins. The UK is a prominent stakeholder in this sector, which is growing in importance as biologics are often more specific to their target in the body and have fewer side effects. The development and production of biologics is, however, a labour and time intensive process. Many promising therapeutic proteins are never commercialised due to problems with self-association (aggregation). Failure of these 'candidate' therapeutics at a late stage of development is expensive to both industry and society as these therapies are usually indicated for serious life-threatening or life-limiting conditions. The aim of this project is to assess the ability of a screen developed by the applicants to identify candidate therapeutics at an early stage of development that are inherently resistant to aggregation. This would reduce the cost of development and reduce the failure rate of promising therapies for serious diseases.
Technical Summary
The project is a collaboration between academics at the University of Leeds and stakeholders in biopharmaceutical production (MedImmune) and their biophysical characterisation (Avacta Group Plc). The objectives of this feasibility award application are:
1. To test whether an in vivo screen that reports on the aggregation of proteins/peptides in the periplasm of E. coli can be used (a) to predict bioprocessibility of candidate sequences of diverse protein platforms directly after affinity panning (b) to facilitate re-design of a previously identified candidate with high target affinity but poor biophysical properties and (c) to optimise formulation by quantifying the effects of excipients added to the bacterial growth medium.
2. To miniaturize and automate the screen to allow higher throughput in a 48-well format.
Development of a screen that obviates the need to purify candidates and identifies failures early would reduce the time and cost of biologic development increasing the competitiveness of the industrial biotechnology sector in the UK.
1. To test whether an in vivo screen that reports on the aggregation of proteins/peptides in the periplasm of E. coli can be used (a) to predict bioprocessibility of candidate sequences of diverse protein platforms directly after affinity panning (b) to facilitate re-design of a previously identified candidate with high target affinity but poor biophysical properties and (c) to optimise formulation by quantifying the effects of excipients added to the bacterial growth medium.
2. To miniaturize and automate the screen to allow higher throughput in a 48-well format.
Development of a screen that obviates the need to purify candidates and identifies failures early would reduce the time and cost of biologic development increasing the competitiveness of the industrial biotechnology sector in the UK.
Planned Impact
As described in proposal submitted to TSB
Publications
Ebo JS
(2020)
An in vivo platform to select and evolve aggregation-resistant proteins.
in Nature communications
Saunders JC
(2016)
An in vivo platform for identifying inhibitors of protein aggregation.
in Nature chemical biology
Description | We have found that we can use a simple assay (the survival of bacteria on agar plates that contain an antibiotic) to identify protein-based drugs that will be robust to the stresses applied to them during manufacture. We have also shown that we can use evolution approaches to re-design aggregation-prone proteins. |
Exploitation Route | This work led to two follow-on PhD studentships with Astra Zeneca and one with UCB. A high impact paper on the method development has been published at Nature Commun. |
Sectors | Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology |
Description | This proof of concept study has led to great interest from the wider biopharmaceutical sector. We have an active collaboration with UCB and are in discussion with several other companies. |
First Year Of Impact | 2016 |
Sector | Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology |
Description | Mechanistic Biology and its strategic application |
Amount | £10,099,355 (GBP) |
Funding ID | BB/T007222/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2020 |
End | 09/2028 |
Description | Next Gen MIC concurrent selection for affinity and developability of evolved candidates |
Amount | £103,929 (GBP) |
Funding ID | BB/W510403/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2021 |
End | 09/2025 |
Description | White Rose Doctoral Training Partnership in Mechanistic Biology and its Strategic Application |
Amount | £10,864,458 (GBP) |
Funding ID | BB/M011151/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 09/2015 |
End | 09/2023 |
Description | Screen |
Organisation | AstraZeneca |
Department | MedImmune |
Country | United Kingdom |
Sector | Private |
PI Contribution | Developed a screen that may predict the manufacturability of biopharmaceuticals. |
Collaborator Contribution | Access to wide variety of well characterised biopharmaceutical candidates |
Impact | Still on-going. The grant is Innovate / BBSRC feasibility award |
Start Year | 2015 |
Description | Webinar with Technology Networks |
Form Of Engagement Activity | Engagement focused website, blog or social media channel |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | The aim was to explain and advertise the assay developed in this grant. |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.technologynetworks.com/tn/webinars/using-ecoli-to-identify-stability-liabilities-in-ther... |